checkAd

    Titan Pharmaceuticals--die Chance für 2000 - 500 Beiträge pro Seite

    eröffnet am 13.02.00 17:49:20 von
    neuester Beitrag 24.07.01 09:59:48 von
    Beiträge: 61
    ID: 63.486
    Aufrufe heute: 0
    Gesamt: 5.176
    Aktive User: 0

    ISIN: US8883145075 · WKN: A2PB5B
    0,1260
     
    EUR
    -14,29 %
    -0,0210 EUR
    Letzter Kurs 30.11.20 Tradegate

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    9,6200+62,77
    0,6171+62,39
    1,8900+48,82
    10,500+34,62
    3,1600+31,67
    WertpapierKursPerf. %
    1,0100-23,48
    2,2700-25,51
    0,6040-29,19
    2,1500-32,81
    3,0600-37,55

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 13.02.00 17:49:20
      Beitrag Nr. 1 ()
      hallo,

      hier mal wieder eine aktie der eine "große" ZUKUNFT bevor steht

      sind zwar derletzt auch schon schön gestiegen-- aber hier ist eine zeitnahe verwirklichung im gange -- haben kooperation mit der schering ag über die herstellung von medikamenten gegen schizophrenie begonnen... ist ein riesengroßer markt... immer mehr institutionelle anleger decken sich momentan mit dieser aktie ein... bin selbst bei 17 eingestiegen werde aber morgen noch einmal nachkaufen!!!
      weitere infos zum unternehmen: ...ist eine holding für mehrere kleine biotech - firmen... decken die bereiche krebsforscchung, parkinson und wie erwähnt schizophrenie ab... iloperidon soll das medikament gegen schizophrenie heißen... 5 milliarden mark markt... kommt in ca. 1-2 jahren auf den markt...

      weitere empfehlungen:

      aurora bio-- aber schon extrem gestiegen
      inhale pharma
      andrx

      viel erfolg und grüsse

      schachi
      Avatar
      schrieb am 13.02.00 21:53:03
      Beitrag Nr. 2 ()
      Ja Leute, habe einige meine Werte als NAS Symbol,

      Symbol Last Change %Change Volume Position Bought Value Net %Change %Total Actions
      HGSI 149.75
      IMCL 70.00
      IMGN 17.00
      IMNR 9.81
      MEDI 157.38
      MLNM 212.50
      AVAN 9.25
      TRIBY 3.81
      TTP 31.25
      AVIR 26.62
      NGEN 54.75
      PPCO 17.12

      So, das sind meine Werte zum teil selbst investiert such noch weitere..

      Habt Ihr auch eine Depot oder Watchlist die wir mal austauschen können.

      Übrigens an Titan Pharmaceutics glaube ich auch und habe das papier auch schon....

      TS
      Avatar
      schrieb am 14.02.00 00:03:28
      !
      Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
      Avatar
      schrieb am 16.02.00 22:43:15
      Beitrag Nr. 4 ()
      hallo,

      ich denke in den nächsten tagen geht diese aktie nur noch nach norden-- guter tipp -- DECKT EUCH EIN...
      es ist einiges im gange... schaut auch mal im yahoo board nach... manche leute die bei norvatis arbeiten dürfen noch nicht alles über das potential dieses unternehmens preisgeben!!!!!!

      viel erfolg an alle

      grüße

      schachi
      Avatar
      schrieb am 17.02.00 11:54:36
      Beitrag Nr. 5 ()
      Ah, ich sehe hier sind einmal keine pusher am Werk. Wollte mich schon fast hier aus Wallstreet-board verabschieden, wegen den ganzen pushern und zockern. Die meissten bringen nur hohles gebrabbel ohne fundamentale Daten.

      Titan Pharmaceuticals habe ich zufällig letzte Woche bei Yahoo finance in USA gelesen. Haben durch die Kooperation mit der Deutschen Schering und Entwicklungs chancen. Sie werden in der Zukunft nicht allzuweit entfernt mit Schering ein Parkinson Medikament auf den Markt bringen. Ihr wisst ja selber wieviel Prominente inzwischen an Parkinson erkrankt sind.

      In Alzheimer und Parkinson Medikamenten sind sehr grosse Zukunftaussichten.

      Ich habe auch schon gekauft.

      MLNM sitzt seit letzten August schon in meinem Depot.


      Werde beide noch lange halten und mich an den Gewinnen erfreuen.

      Ciao, and many $$$$$$$$$$$$$$$$$$$$$$$$$$$!

      Trading Spotlight

      Anzeige
      Genau jetzt noch vor Fortsetzung der neuen Rallye rein? mehr zur Aktie »
      Avatar
      schrieb am 17.02.00 22:21:15
      Beitrag Nr. 6 ()
      hallo an alle!!!!!

      habt ihr euch auch schon eingedeckt????????

      es ist nicht auszudenken was passiert, wenn die ergenisse der novartiskonferenz raus sind!!!!!!

      ich denke die 100 werden innerhalb von 4 monaten geasehen.

      natürlich nur meine meinung wen es aber interessiert schaut doch mal bitte im yahoo board nach!!!!!!!!

      viel erfolg an alle

      schachi

      p.s. wen es immer noch interessiert sollte sich folgende werte auch einmal genauer anschauen:

      ANDRX
      INHALE
      AURORA BIOSCIENCES

      ich kann alle nur wärmstens empfehlen, egal wie sehr sie auch schon gelaufen sind!!!!!!!
      Avatar
      schrieb am 24.02.00 18:24:41
      Beitrag Nr. 7 ()
      hi schachi

      Kannst du mir sagen wann die Novartiskonferenz stattfindet bzw. ob sie schon stattgefunden hat ?

      Hab mir die Aktie gekauft....bin davon überzeugt das sie nach norden abgeht.

      cu
      cineman
      Avatar
      schrieb am 24.02.00 18:43:27
      Beitrag Nr. 8 ()
      Ist das gerade eine Konsolidierung oder gibts bad news? Möchte auch einsteigen? Jetzt Kaufkurse?


      Danke für Eure Meinungen!

      Kommdirekt
      Avatar
      schrieb am 25.02.00 09:15:48
      Beitrag Nr. 9 ()
      hallo an alle,

      auch ich habe gestern abend nicht ganz glauben können was hier abgeht.

      zuerst dieser tiefe sturz und in der letzten handelsstunde in usa zieht der kurs mit "DICKEN" orders wieder nach oben und schliesst im plus.
      zeigt, dass hier einige institutionelle zu sehr billigen kursen eingestiegen sind!!!!!
      übrigens am 15. märz soll es berichte und pressekonferenz zur novartiskonferenz geben.
      ich denke wir haben immer noch kaufkurse, wobei die nächste woche noch sehr volatilö sein dürfte.....


      viel erfolg an alle

      schachi
      Avatar
      schrieb am 25.02.00 13:17:44
      Beitrag Nr. 10 ()
      hallo,

      titan hat vor wenigen minuten mitteilen lassen, dass es ein private placement geben wird von 42 mio $....
      ausgewählte kreise erhalten die aktie für 32,50$...
      das bedeutet deckt euch mit aktien ein...

      viel erfolg an alle

      schachi
      Avatar
      schrieb am 25.02.00 14:02:05
      Beitrag Nr. 11 ()
      Schaut mal unter www.juchu.de, da wird Titan empfohlen.

      mfg
      Carroll
      Avatar
      schrieb am 01.03.00 19:15:25
      Beitrag Nr. 12 ()
      an alle die TITAN Pharm. besitzen *ggg*

      haben seid letzter Woche (als das private placement von 42 mio $ kam)
      ......über 50% zugelegt !!!!!

      Ich muß sagen, diese Aktie wird uns noch sehr viel freude machen, davon bin ich überzeugt.

      Weiß vielleicht jemand wer bzw. welche Firmen sich TITAN-Aktien (42 mio. $) geordert hat ? würd mich interessieren wer sich auch was vom Kuchen gönnen möchte .
      viel spaß noch.....

      cineman
      Avatar
      schrieb am 04.03.00 16:13:37
      Beitrag Nr. 13 ()
      hi leute,

      hier etwas für euch

      Titan Pharm Reiterated `Strong Buy` at Deutsche
      Banc AB
      By Donna Mcdonald

      Princeton, New Jersey, Feb. 25 (Bloomberg Data) -- Titan Pharmaceuticals
      Inc. (TTP US) was reiterated ``strong buy`` by analyst Kevin C. Tang at
      Deutsche Banc Alex. Brown. The 12-month price target was raised to $59 from
      $34 per share.
      Avatar
      schrieb am 13.03.00 15:56:27
      !
      Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
      Avatar
      schrieb am 23.03.00 14:02:47
      Beitrag Nr. 15 ()
      Stufe 3 bei der medikamentenentwicklung ist erreicht.
      stufe 4 ist der durchbruch.............
      ein medikament gegen alzheimer entdecken.....
      bin leider heute erst aufgesprungen, aber sehe den wert
      über 12 monate als einen treffer.
      Avatar
      schrieb am 24.03.00 09:00:30
      Beitrag Nr. 16 ()
      hallo an alle,

      gestern kamen gute neuigkeiten und zahlen für 1999 raus... sieht sehr gut aus, diese aktie ist definitiv wieder auf dem sprung zu alten höhen....-- wenn dass nur alle wären, jammer, naja auch bei den folgenden lohnt es sich zu investieren...

      flamel-- unentdeckt schwer zu kriegen in brd... steht bei 7-8 kursziel 25 zum ende des jahres habe meine ersten zum höchstkurs von 12 gekauft aber immer wieder nachgekauft

      penwest-- steht bei 16 kursziel 25

      viel glück an alle

      schachi
      Avatar
      schrieb am 26.03.00 10:59:45
      Beitrag Nr. 17 ()
      hoffentlich kann sich der kurs jetzt halten und
      weiter nach vorn schreiten.
      was meint ihr kurz gewinn mitnehmen und mitte der woche wieder
      einsteigen.

      kurssteigerung war ja klar die auswirkung der jahreszahlen.
      Avatar
      schrieb am 26.03.00 20:39:09
      Beitrag Nr. 18 ()
      Hallo Schachi,

      na ja habe meine Titan zu 47 verkauft und warte eigentlich auf eine Bodenbildung. Den 30ger Einstiege habe ich nicht mitgenommen, könnte mich grün und blau ärgern....

      Aber wie geht es weiter, ist der Hype erst mal rum, und kommt in 200 Tagen wieder, oder gehts nach der Korrektur wieder munter nordwärts?

      Wenn mans halt wüste...

      Viele Grüße
      TS
      Avatar
      schrieb am 27.03.00 09:10:15
      Beitrag Nr. 19 ()
      hallo totalstock,

      wie geht`s weiter?? wer weiss das schon, klar ist allerdings, dass es bei dieser aktie den grossen schlag tun wird... wann weiss ich natürlich nicht... sie geht auf jedenfall nach oben...
      schau dir dazu vielleicht einmal auf den amerikanischen yahoo message board die seite von ttp-- titan an... da posten einige leute die sehr sehr viel wissen... schau mal rein... steig so schnell wie möglich wieder ein!! nue ein tipp... viel erfolg an alle

      grüsse

      schachi
      Avatar
      schrieb am 29.03.00 07:33:37
      Beitrag Nr. 20 ()
      Tuesday March 28, 8:32 am Eastern Time
      Company Press Release
      SOURCE: Donner Corporation International
      Donner Corp. International Reiterates its Buy Recommendation On Titan Pharmaceuticals, Inc.
      SANTA ANA, Calif., March 28 /PRNewswire/ -- The following is being issued by Donner Corporation International, a member firm of the National Association of Securities Dealers, CDR number 37702.

      Donner Corp. International, a Santa Ana, California-based investment banking and institutional research firm, today reiterated its Buy Recommendation on Titan Pharmaceuticals, Inc. (Amex: TTP - news). Titan Pharmaceuticals, Inc. is a South San Francisco, California-based biopharmaceutical company that develops medicines addressing central nervous system disorders and cancer.

      Donner believes that the recent downturn in the biotechnology sector resulted largely from the comments by President Clinton and British Prime Minister Tony Blair on the human genome project, but that the strong fundamentals of many biotechnology companies remain the same. Titan Pharmaceuticals is one such company with enormous potential from the products in its pipeline, particularly Zomaril(TM), which is in phase III clinical trials and is being developed by Novartis Pharma AG for the treatment of schizophrenia; Cea-Vac(TM), which is in phase III clinical trials for colorectal cancer; and Spheramine(TM), which is in phase I/II clinical trials and is being developed by Schering AG for the treatment of Parkinson`s disease. Donner believes that the biotechnology sector is in its recovery stage and on its way up. Thus, Donner reiterates its Buy Recommendation on Titan Pharmaceuticals.

      The updated Donner report contains financial data from Fiscal Year 1999 and is an addendum to the report issued on February 18, 2000. For copies of both reports, please contact Donner Corp. International at (800) 324-6050.

      (The information contained herein is based on sources believed to be reliable but is not guaranteed by this company and is not comprehensive. It is not to be construed as an offer or the solicitation of an offer to sell or buy the securities mentioned herein. This company, its members, affiliates, employees, related accounts may have long or short positions, which could be substantial, in securities discussed or recommended and may purchase, sell, or trade these securities from time to time in the open market or otherwise. In addition, this company may from time to time, perform investment banking, corporate finance, provide services for, and solicit investment banking, corporate finance or other business from the issuers of such securities for various fees, which comprise of, in part or in whole, a one-time retainer fee, basic monthly service fees, fees for other services, and/or compensation in the form of the issuer`s securities for a fee.)
      SOURCE: Donner Corporation International
      Avatar
      schrieb am 30.03.00 21:47:59
      Beitrag Nr. 21 ()
      Hi Leute!

      Denke daß unsere "Titanic" bald den Grund erreicht haben wird. Denke weiters, daß sie eine der ersten sein wird, welche wieder Luft und Sonne sieht, wenn die "Meute" von Bord gehüpft ist. Frauen und Kinder zuerst. Meine Füße kleben an den Bordplanken - hoffentlich geht mir unter Wasser nicht die Luft aus.

      Bis denn
      delta2
      Avatar
      schrieb am 31.03.00 07:51:41
      Beitrag Nr. 22 ()
      Bichen lang, aber wichtig zum nachschauen.
      March 30, 2000

      TITAN PHARMACEUTICALS INC (TTP)
      Annual Report (SEC form 10-K)
      MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
      OF OPERATIONS.


      THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH THE CONSOLIDATED

      FINANCIAL STATEMENTS AND NOTES THERETO APPEARING ELSEWHERE IN THIS REPORT.



      THE FOLLOWING DISCUSSION CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS, WITHIN

      THE MEANING OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT

      OF 1995, THE ATTAINMENT OF WHICH INVOLVES VARIOUS RISKS AND UNCERTAINTIES.

      FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING

      TERMINOLOGY SUCH AS "MAY," "WILL," "EXPECT," "BELIEVE," "ESTIMATE,"

      "ANTICIPATE," "CONTINUE," OR SIMILAR TERMS, VARIATIONS OF THOSE TERMS OR THE

      NEGATIVE OF THOSE TERMS. OUR ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE

      DESCRIBED IN THESE FORWARD-LOOKING STATEMENTS DUE TO, AMONG OTHER FACTORS, THE

      RESULTS OF ONGOING RESEARCH AND DEVELOPMENT ACTIVITIES AND PRE-CLINICAL TESTING,

      THE RESULTS OF CLINICAL TRIALS AND THE AVAILABILITY OF ADDITIONAL FINANCING

      THROUGH CORPORATE PARTNERING ARRANGEMENTS OR OTHERWISE.



      SPHERAMINE-TM-, CEAVAC-REGISTERED TRADEMARK-, TRIAB-REGISTERED TRADEMARK-,

      TRIGEM-TM-, PIVANEX-TM- AND CCM-TM- ARE TRADEMARKS OF TITAN PHARMACEUTICALS,

      INC. ZOMARIL-TM- IS A TRADEMARK OF NOVARTIS PHARMA AG.



      OVERVIEW


      We are a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases.

      Our most advanced product candidate, Zomaril (iloperidone), is a novel antipsychotic agent under development for the treatment of patients with schizophrenia. Zomaril is currently in Phase III clinical testing through a licensing and development agreement with Novartis Pharma AG. Also in the CNS arena, we are developing a unique cell based therapeutic, Spheramine, for the treatment of patients with Parkinson`s disease. In November 1999, we received approval from the FDA to commence Phase I/II clinical testing with Spheramine. We have entered into a collaboration with Schering AG for the development, manufacture and commercialization of this treatment for Parkinson`s disease, and Schering is funding the manufacturing, development and clinical studies of the product in exchange for worldwide commercialization rights. Our cancer portfolio includes three therapeutic monoclonal antibodiesCeaVac, TriAb, and TriGemthat are designed to stimulate a patient`s immune system against cancer cells. CeaVac is currently being evaluated in a large multi-center double-blind placebo-controlled Phase II/ III clinical trial in patients with Stage IV metastatic colorectal cancer. TriAb is currently being evaluated in a double-blind placebo-controlled Phase II clinical study in patients with breast cancer. TriGem has completed initial Phase I testing in patients with melanoma, and we are pursuing later stage clinical trials through co-operative clinical oncology research groups. We are also currently conducting a Phase II clinical trial with Pivanex, a novel synthetic analog of butyric acid, for the treatment of patients with non-small cell lung cancer. Our other programs in pre-clinical development include a cancer gene therapy product and an implantable drug delivery technology.


      RESULTS OF OPERATIONS FOR THE THREE YEARS ENDED DECEMBER 31, 1999, 1998, AND



      1999 COMPARED TO 1998


      Since inception, we have devoted substantially all of our resources to product and technology development, clinical research, raising capital, and securing patent protection. At December 31, 1999, we had an accumulated deficit of $65.4 million and working capital of $45.1 million.

      Revenues in 1999 of $0.3 million consisted primarily of U.S. government grants. There were no revenues for 1998.

      From inception through December 31, 1999, research and development expenses, including $10.3 million in acquired in-process research and development costs, totaled $64.5 million, and general and administrative expenses totaled $24.8 million. Research and development expenses for 1999 were $9.6 million, including $0.1 million of acquired in-process research and development related to the acquisition of the minority interest of Theracell, compared to $7.8 million for 1998, an increase of $1.8 million, or 22%. The planned increase compared to 1998 was attributable to patient enrollment in the clinical trial with CeaVac in colorectal cancer and the final phases of the pre-clinical program for Spheramine in preparation for Phase I/II clinical trial. General and administrative expenses for 1999 were $2.8 million compared to $3.7 million for 1998, a decrease of $0.9 million, or 25%. The decrease was attributable to ongoing efforts to contain non-research operating costs.

      Other income for 1999 was $0.7 million compared to $0.9 million for 1998, a decrease of $0.2 million, or 20%. Other income for 1999 and 1998 primarily consisted of interest income.

      As a result of the foregoing, we had a net loss of $11.3 million in 1999 compared to a net loss of $10.6 million in 1998.

      None of our products have been commercialized, and we do not expect to generate any revenue from product sales or royalties until at least 2002. With the advancement in clinical development of our products, we anticipate research and development expenses will increase in the near future, while general and administrative costs necessary to support such research and development activities will increase at a

      controlled rate. We will also seek to identify new technologies and/or product candidates for possible in-licensing or acquisition. Accordingly, we expect to incur operating losses for the foreseeable future. We cannot assure that we will ever achieve profitable operations.


      1998 COMPARED TO 1997


      There were no revenues for 1998 compared to $17.5 million for 1997. Total revenues for 1997 were comprised of approximately $17.4 million from fees related to the license of Zomaril to Novartis and $0.1 million from U.S. government grants.

      Research and development expenses for 1998 were $7.8 million, as compared to $18.8 million for 1997, a decrease of $11.0 million, or 58%. 1997 expenses include $9.5 million of acquired in-process research and development and other expenditures related to the acquisition of Zomaril, the development of which is now being funded by Novartis pursuant to the partnering agreement established by us and Novartis in November 1997. General and administrative expenses for 1998 were $3.7 million compared to $6.5 million for 1997, a decrease of $2.8 million, or 43%. The decrease is attributable to the merger of a former subsidiary with and into Titan in August 1997, with a subsequent reduction in personnel and other expenses, as well as the reduction in overhead associated with the sale of a research technology by Ingenex in June 1997.

      Other income for 1998 was $0.9 million compared to $8.4 million for 1997. Other income for 1998 includes interest income of $0.8 million. Other income for 1997 includes a gain of $8.4 million from the sale of a research technology, net interest income of $0.4 million, and a loss of $0.6 million representing our share of the losses of Ansan Pharmaceuticals, Inc., our former subsidiary.

      We had a net loss of $10.6 million in 1998 compared to net income of $0.6 million in 1997.


      LIQUIDITY AND CAPITAL RESOURCES


      We have funded our operations since inception primarily through our initial public offering and private placements of our securities, as well as proceeds from warrant and option exercises, corporate licensing and collaborative agreements, and government sponsored research grants. Cash has been used in operating activities primarily to fund operating expenses.

      In March 2000, we completed a private placement of 1.2 million shares of our common stock for net proceeds of approximately $38.9 million, after deducting fees and commissions and other expenses of the offering.

      In October 1999, we called for the redemption on November 19, 1999 (the Redemption Date) of our outstanding Class A Warrants for cash at the redemption price of $0.05 per warrant. Rather than surrendering the warrants for redemption, warrant holders had the option to purchase our common stock at a price of $6.02 per share before the Redemption Date. The warrant call resulted in 7.1 million, or 99.4%, of our outstanding Class A Warrants being exercised with net proceeds to us of $39.4 million, after deducting advisory fees and other related expenses.

      In January 1999, we completed a private placement of 2.3 million shares of our common stock for net proceeds of $5.8 million, after deducting fees and commissions and other expenses of the offering.

      During 1997, we received $25.9 million from license fees related to the Novartis sublicense and the sale of a research technology.

      In January 1997, we entered into an exclusive license agreement with Hoechst Marion Roussel, Inc., (Hoechst) pursuant to which we received the worldwide patent rights and know-how related to the antipsychotic agent Zomaril. During 1997, we paid fees consisting of:

      (i) $4.0 million in cash, and

      (ii) $5.5 million through the issuance of approximately 0.6 million shares of common stock (the Hoechst Shares.)

      We were obligated to pay the difference between $5.5 million and the net proceeds received by Hoechst upon the sale of the Hoechst Shares. In February 1998, Hoechst received net proceeds of $2.5 million on the sale of the Hoechst Shares. Accordingly, in March 1998, we paid to Hoechst $3.0 million.

      We have entered into various agreements with research institutions, universities, and other entities for the performance of research and development activities and for the acquisition of licenses related to those activities. The aggregate commitments we have under these agreements, including minimum license payments, for the next 12 months is approximately $1.5 million. Certain of the licenses provide for the payment of royalties by us on future product sales, if any. In addition, in order to maintain license and other rights while products are under development, we must comply with customary licensee obligations, including the payment of patent related costs and meeting project-funding milestones.

      We expect to continue to incur substantial additional operating losses from costs related to continuation and expansion of product and technology development, clinical trials, and administrative activities. To preserve operating capital, we have chosen to strategically focus on development of our later stage products in clinical development, and at least temporarily reduce or eliminate spending on certain pre-clinical programs. We believe that we currently have sufficient working capital to sustain our planned operations at least through 2003.

      Our cash and investment policy emphasizes liquidity and preservation of principal over other portfolio considerations. We select investments that maximize interest income to the extent possible given these two constraints. We satisfy liquidity requirements by investing excess cash in securities with different maturities to match projected cash needs and limit concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers.


      YEAR 2000 COMPLIANCE


      In prior years, we discussed the nature and progress of our Year 2000 readiness. In late 1999, we completed remediation and testing of systems at minimal cost. As a result of those planning and implementation efforts, we experienced no significant disruptions in mission critical information technology and non-information technology systems and believe those systems successfully responded to the Year 2000 date change. We are not aware of any material problems resulting from the Year 2000 issue, either with our products under development, internal systems, or the products and services of third parties. We will continue to monitor our mission critical computer applications and our suppliers and vendors throughout the year to ensure that any latent Year 2000 matters that may arise are addressed promptly.


      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


      We have reviewed the requirements of Item 7A and have determined that these disclosures are not applicable.


      ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.


      The response to this item is included in a separate section of this Report. See "Index to Consolidated Financial Statements" on Page F-1.


      ITEM 9. CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL

      DISCLOSURE.


      Not applicable.


      ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF REGISTRANT.


      The following table sets forth the names, ages and positions of our executive officers and directors.


      NAME AGE POSITION
      ---- -------- --------
      Louis R. Bucalo, M.D. (1)....................... 41 Chairman, President and Chief Executive Officer
      Sunil Bhonsle................................... 50 Executive Vice President and Chief Operating
      Officer
      Richard C. Allen, Ph.D.......................... 57 Executive Vice President
      Robert E. Farrell............................... 50 Executive Vice President and Chief Financial
      Officer
      Victor Bauer, Ph.D.............................. 64 Executive Director of Corporate Development and
      Director
      Ernst-Gunter Afting, M.D., Ph.D. (2)............ 57 Director
      Eurelio M. Cavalier............................. 67 Director
      Michael K. Hsu (2).............................. 51 Director
      Hubert Huckel, M.D. (1)(3)...................... 68 Director
      Marvin E. Jaffe, M.D. (1)(3).................... 63 Director
      Konrad M. Weis, Ph.D. (1)....................... 71 Director

      (1) Member of Executive Committee

      (2) Member of Audit Committee

      (3) Member of Compensation Committee

      LOUIS R. BUCALO, M.D. is a founder of Titan and has served as our President and Chief Executive Officer since January 1993. Dr. Bucalo has served as a director of Titan since March 1993 and was elected Chairman of the Board of Directors in January 2000. From July 1990 to April 1992, Dr. Bucalo was Associate Director of Clinical Research at Genentech, Inc., a biotechnology company. Dr. Bucalo holds an M.D. from Stanford University and a B.A. in biochemistry from Harvard University.

      SUNIL BHONSLE joined us as Executive Vice President and Chief Operating Officer in September 1995. Mr. Bhonsle served in various positions, including Vice President and General Manager-Plasma Supply and Manager-Inventory and Technical Planning, at Bayer Corporation from July 1975 until April 1995. Mr. Bhonsle holds an M.B.A. from the University of California at Berkeley and a B.Tech. in chemical engineering from the Indian Institute of Technology.

      RICHARD C. ALLEN, PH.D., joined us as Executive Vice President in August 1995. From January 1995 until it was merged into Titan in March 1999, he also served as President and Chief Executive Officer of Theracell. From June 1991 until December 1994, Dr. Allen was Vice President and General Manager of the Neuroscience Strategic Business Unit of Hoechst-Roussel Pharmaceuticals, Inc. Dr. Allen holds a Ph.D. in medicinal chemistry and a B.S. in pharmacy from the Medical College of Virginia.

      ROBERT E. FARRELL joined us as Executive Vice President and Chief Financial Officer in September 1996. Mr. Farrell was employed by Fresenius USA, Inc. from 1991 until August 1996 where he served in various capacities, including Vice President Administration, Chief Financial Officer and General Counsel. His last position was Corporate Group Vice President. Mr. Farrell holds a B.A. from University of Notre Dame and a J.D. from Hastings College of Law, University of California.

      VICTOR J. BAUER, PH.D., has served as a director of Titan since November 1997. Dr. Bauer joined us in February 1997, and currently serves as Executive Director of Corporate Development. From April 1996 until its merger into Titan, Dr. Bauer also served as a director and Chairman of Theracell. From December 1992 until February 1997, Dr. Bauer was a self-employed consultant to companies in the pharmaceutical and biotechnology industries. Prior to that time, Dr. Bauer was with Hoechst-Roussel Pharmaceuticals Inc., where he served as President from 1988 through 1992.

      ERNST-GUNTER AFTING, M.D., PH.D., has served as a director of Titan since May 1996. Dr. Afting has served as the President of the GSF-National Center for Environment and Health, a government research center in Germany, since 1995. From 1984 until 1995, he was employed in various capacities by the Hoechst Group, serving as Divisional Head of the Pharmaceuticals Division of the Hoechst Group from 1991 to 1993 and as President and Chief Executive Officer of Roussel Uclaf (a majority stockholder of Hoechst AG) in Paris from 1993 until 1995.

      EURELIO M. CAVALIER has served as a director of Titan since September 1998. From 1958 until his retirement in 1994, Mr. Cavalier was employed in various capacities by Eli Lilly & Co., serving as Vice President Sales from 1976 to 1982 and Group Vice President U.S. Pharmaceutical Business Unit from 1982 to 1993. Mr. Cavalier currently serves on the Boards of Directors of DataChem, Inc., ProSolv, Inc. and St. Vincent Hospital. He serves on the Advisory Board of COR Therapeutics and Indiana Heart Institute.

      MICHAEL K. HSU has served as a director of Titan since March 1993. He is currently a General Partner of EndPoint Merchant Group, a merchant bank specializing in making investments into the healthcare and life science industries. Mr. Hsu served as Director-Corporate Finance of National Securities Corp. from November 1995 through April 1998, and from November 1994 through October 1995 served with Coleman and Company Securities in the same capacity. Mr. Hsu previously held various executive positions with Steinberg and Lyman Health Care Company, Ventana Venture Growth Fund, Asian Pacific Venture Group (Thailand) and D. Blech Life Science Ventures.

      HUBERT HUCKEL, M.D. has served as a director of Titan since October 1995. From 1964 until his retirement in December 1992, Dr. Huckel served in various positions with The Hoechst Group. At the time of his retirement, he was Chairman of the Board of Hoechst-Roussel Pharmaceuticals, Inc., Chairman and President of Hoechst-Roussel Agri-Vet Company and a member of the Executive Committee of Hoechst Celanese Corporation. He currently serves on the Board of Directors of Thermogenesis, Corp. and Gynetics, Inc.

      MARVIN E. JAFFE, M.D. has served as a director of Titan since October 1995. From 1988 until April 1994, Dr. Jaffe served as President of R.W. Johnson Pharmaceutical Research Institute where he was responsible for the research and development activities in support of a number of Johnson & Johnson companies, including ORTHO-McNeil Pharmaceuticals, ORTHO Biotech and CILAG. From 1970 until 1988, he was Senior Vice President of the Merck Research Laboratories. He currently serves on the Boards of Directors of Celltech Group, plc, Immunomedics, Inc., Matrix Pharmaceuticals, Inc., and Vanguard Medica, plc.

      KONRAD M. WEIS, PH.D., has served as a director of Titan since March 1993. Dr. Weis is the former President and Chief Executive Officer of Bayer Corporation. Dr. Weis serves as a director of PNC Equity Management Company, Michael Baker Corporation, Visible Genetics, Inc. and Demegen, Inc.

      Directors serve until the next annual meeting or until their successors are elected and qualified. Officers serve at the discretion of the Board of Directors, subject to rights, if any, under contracts of employment. See "Item 11. Executive CompensationEmployment Agreements."


      DIRECTOR COMPENSATION


      During 1999, non-employee directors are entitled to receive annual options to purchase 10,000 shares of common stock vesting quarterly as fees for the Board of Directors meetings, and are reimbursed for their expenses in attending such meetings. Directors are not precluded from serving us in any other capacity and receiving compensation therefor. In addition, directors are entitled to receive options (Director Options) pursuant to our 1998 Stock Option Plan. In August 1999, each of our current directors received Director Options to purchase 5,000 shares of common stock at an exercise price of $9.063 per share.

      We are a party to a consulting agreement with Dr. Afting pursuant to which he receives fees of $7,000 annually.

      We are a party to a consulting agreement with Dr. Jaffe pursuant to which he receives fees of $35,000 annually.


      BOARD COMMITTEES AND DESIGNATED DIRECTORS


      The Board of Directors has an Executive Committee, a Compensation Committee and an Audit Committee. The Executive Committee exercises all the power and authority of the Board of Directors in the management of Titan between Board meetings, to the extent permitted by law. The Compensation Committee makes recommendations to the Board concerning salaries and incentive compensation for our officers and employees and administers our stock option plans. The Audit Committee reviews the results and scope of the audit and other accounting related matters.

      The Board of Directors met four times during 1999 and also took action by unanimous written consent. The Executive Committee met one time and also took action by unanimous written consent, and the Compensation Committee and Audit Committee each met one time. Each of our current directors attended at least 75% of the aggregate of (i) the meetings of the Board of Directors and (ii) meetings of any Committees of the Board on which such person served which were held during the time such person served.


      COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934


      Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Such executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish us with copies of all Section 16(a) forms filed by such reporting persons.

      Based solely on our review of such forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable to our executive officers, directors and greater than 10% beneficial owners were complied with.


      ITEM 11. EXECUTIVE COMPENSATION.


      The following summary compensation table sets forth the aggregate compensation awarded to, earned by, or paid to the Chief Executive Officer and to executive officers whose annual compensation exceeded $100,000 for the fiscal year ended December 31, 1999 (collectively, the "named executive officers") for services during the fiscal years ended December 31, 1999, 1998 and 1997:


      SUMMARY COMPENSATION TABLE

      ANNUAL COMPENSATION
      --------------------------------
      NAME AND PRINCIPAL POSITION YEAR SALARY BONUS
      --------------------------- -------- -------- ----------
      Louis R. Bucalo ............................................ 1999 $222,013 $ 0
      President and Chief Executive Officer 1998 $243,100 $ 0
      1997 $231,525 $58,721(1)
      Sunil Bhonsle .............................................. 1999 $180,100 $ 0
      Executive Vice President and 1998 $194,800 $ 0
      Chief Operating Officer 1997 $190,991 $68,370(1)
      Richard C. Allen ........................................... 1999 $180,475 $ 0
      Executive Vice President (2) 1998 $197,800 $ 0
      1997 $193,984 $77,096(1)
      Robert E. Farrell .......................................... 1999 $173,425 $ 0
      Executive Vice President and 1998 $190,400 $ 0
      Chief Financial Officer 1997 $186,665 $18,500

      (1) Bonuses pertain to fiscal year 1995 and were paid in 1997.

      (2) Dr. Allen also served as President and Chief Executive Officer of Theracell until Theracell merged with and into Titan in March 1999, and President and Chief Operating Officer of ProNeura during these periods. Until March 1999, Dr. Allen received his entire salary from Theracell. Dr. Allen`s bonus in 1997 included $20,000 paid by Titan.


      OPTION GRANTS IN LAST FISCAL YEAR

      The following table contains information concerning the stock option grants made to the named executive officers during the fiscal year ended December 31, 1999. No stock appreciation rights were granted to these individuals during such year.

      INDIVIDUAL GRANT
      NUMBER OF ------------------------------------------
      SECURITIES % OF TOTAL
      UNDERLYING OPTIONS GRANTED EXERCISE OR
      OPTIONS TO EMPLOYEES BASE PRICE EXPIRATION
      NAME GRANTED FISCAL YEAR ($/SH) (1) DATE
      ---- ---------- --------------- ----------- ----------
      Louis R. Bucalo............................... 71,500 5.35% $ 3.625 01/04/2009
      Louis R. Bucalo............................... 28,000 2.09% $ 3.688 02/04/2009
      Louis R. Bucalo............................... 27,531 2.06% $ 0.080 03/10/2009
      Louis R. Bucalo............................... 5,000 0.37% $ 9.063 08/30/2009
      Louis R. Bucalo............................... 400,000 29.91% $12.750 11/24/2009
      Sunil Bhonsle................................. 55,600 4.16% $ 3.625 01/04/2009
      Sunil Bhonsle................................. 21,000 1.57% $ 3.688 02/04/2009
      Sunil Bhonsle................................. 184,000 13.76% $12.750 11/24/2009
      Richard C. Allen.............................. 41,200 3.08% $ 3.625 01/04/2009
      Richard C. Allen.............................. 21,000 1.57% $ 3.688 02/04/2009
      Richard C. Allen.............................. 132,000 9.87% $12.750 11/24/2009
      Robert E. Farrell............................. 26,300 1.97% $ 3.625 01/04/2009
      Robert E. Farrell............................. 21,000 1.57% $ 3.688 02/04/2009
      Robert E. Farrell............................. 66,000 4.93% $12.750 11/24/2009

      (1) The exercise price may be paid in cash, in shares of common stock valued at the fair market value on the exercise date or through a cashless exercise procedure involving a same-day sale of the purchase shares. We may also finance the option exercise by loaning the optionee sufficient funds to pay the

      exercise price for the purchased shares, together with any federal and state income tax liability incurred by the optionee in connection with such exercise.


      AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES


      The following table sets forth information concerning option exercises and option holdings for the fiscal year ended December 31, 1999 with respect to the named executive officers. No stock appreciation rights were exercised during such year or were outstanding at the end of that year.


      NUMBER OF SECURITIES
      UNDERLYING UNEXERCISED VALUE OF UNEXERCISED IN-THE-
      SHARES OPTIONS AT FY-END MONEY OPTIONS AT FY-END (1)
      ACQUIRED --------------------------- ----------------------------
      NAME ON EXERCISE EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
      ---- ----------- ----------- ------------- ----------- --------------
      Louis R. Bucalo.................. -0- 754,130 473,044(2) $9,937,731 $3,439,758(2)
      Sunil Bhonsle.................... -0- 403,678 231,621(2) $5,590,912 $1,863,912(2)
      Richard C. Allen................. -0- 308,515 153,169(2) $4,868,737 $1,168,360(2)
      Robert E. Farrell................ 21,000 170,966 94,234 $2,085,619 $ 768,650

      (1) Based on the fair market value of our common stock at year-end, $19.000 per share, less the exercise price payable for such shares.

      (2) A portion of employee`s options are immediately exercisable. Upon the employee`s cessation of service, we have the right to repurchase any shares acquired pursuant to said grant. Our right to repurchase shares expires in equal monthly installments over the five year period commencing on the date of grant. Options to which our repurchase right has not expired are deemed unexercisable for purposes of this table.


      EMPLOYMENT AGREEMENTS


      We are a party to an employment agreement with Dr. Bucalo expiring in February 2003 which provides for a base annual salary of $210,000, subject to annual increases of 5% and bonuses of up to 25% at the discretion of the Board of Directors. In the event of the termination of the agreement with Dr. Bucalo, other than for reasons specified therein, we are obligated to make severance payments equal to his base annual salary for the greater of the balance of the term of the agreement or 18 months.

      Employment agreements with each of Dr. Allen, Mr. Bhonsle and Mr. Farrell provide for a base annual salary of $185,000 subject to automatic annual increases based on increases in the consumer price index, and bonuses of up to 20% at the discretion of the Board of Directors. In the event the employee`s employment is terminated other than for "good cause" (as defined), we are obligated to make severance payments equal to the base annual salary for six months. All of the agreements contain confidentiality provisions.

      In order to preserve our cash resources, we have determined, and the executives agreed, that the 1999 salaries of Drs. Bucalo and Allen and Messrs. Bhonsle and Farrell would be at $219,000, $178,000, $178,000 and $171,000, respectively.


      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.


      The following table sets forth, as of March 24, 2000, certain information concerning the beneficial ownership of our common stock by (i) each stockholder known by us to own beneficially five percent or

      more of our outstanding common stock; (ii) each director; (iii) each executive officer; and (iv) all of our executive officers and directors as a group, and their percentage ownership and voting power.


      SHARES BENEFICIALLY PERCENT OF SHARES
      NAME AND ADDRESS OF BENEFICIAL OWNER (1) OWNED (2) BENEFICIALLY OWNED
      ---------------------------------------- ------------------- ------------------
      Louis R. Bucalo, M.D........................................ 1,167,685(3) 4.5%
      Ernst-Gunter Afting, M.D., Ph.D............................. 24,000(4) *
      Richard C. Allen, Ph.D...................................... 349,108(5) 1.4%
      Victor J. Bauer, Ph.D....................................... 65,449(6) *
      Sunil Bhonsle............................................... 480,249(7) 1.9%
      Eurelio M. Cavalier......................................... 12,500(4) *
      Robert E. Farrell........................................... 200,217(8) *
      Michael K. Hsu.............................................. 52,167(9) *
      Hubert Huckel, M.D.......................................... 136,500(10) *
      Marvin E. Jaffe, M.D........................................ 29,661(11) *
      Konrad M. Weis, Ph.D........................................ 76,401(12) *
      Lindsay A. Rosenwald, M.D. ................................. 1,509,294(13) 5.8%
      787 Seventh Avenue, 48th Floor
      New York, NY 10019
      All executive officers and directors as a group 2,593,937 10.1%
      (11) persons..............................................

      * Less than one percent.

      (1) Unless otherwise indicated, the address of such individual is c/o Titan Pharmaceuticals, Inc., 400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080.

      (2) In computing the number of shares beneficially owned by a person and the percentage ownership of a person, shares of our common stock subject to options held by that person that are currently exercisable or exercisable within 60 days are deemed outstanding. Such shares, however, are not deemed outstanding for purposes of computing the percentage ownership of each other person. Except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock.

      (3) Includes 867,454 shares issuable upon exercise of outstanding options.

      (4) Represents shares issuable upon exercise of outstanding options.

      (5) Includes 344,108 shares issuable upon exercise of outstanding options.

      (6) Includes 60,449 shares issuable upon exercise of outstanding options.

      (7) Includes 463,249 shares issuable upon exercise of outstanding options.

      (8) Includes 169,217 shares issuable upon exercise of outstanding options.

      (9) Includes 32,166 shares issuable upon exercise of outstanding options.

      (10) Includes 26,500 shares issuable upon exercise of outstanding options. Includes 100,000 shares held by a family partnership for which Dr. Huckel serves as general partner.

      (11) Includes 26,500 shares issuable upon exercise of warrants and outstanding options.

      (12) Includes 31,617 shares issuable upon exercise of outstanding options.

      (13) Includes (i) 45,042 shares held by each of June Street Corporation and Huntington Street Corporation, companies wholly-owned by Dr. Rosenwald; (ii) 580,853 shares held by a fund for which a wholly-owned company of Dr. Rosenwald`s serves as investment manager; and (iii) an aggregate of

      296,377 shares held by two funds for which the same wholly-owned company serves as general partner. Does not include shares owned by Dr. Rosenwald`s wife and his children`s trusts, as to which he disclaims beneficial ownership. The foregoing information is derived from a Schedule 13G/A filed on behalf of Dr. Rosenwald on February 14, 2000.


      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.


      In June and July of 1997, Dr. Hubert Huckel, a director of Titan, received an aggregate of $155,000 in consulting fees for services rendered in connection with our consummation of the Zomaril (iloperidone) license. Dr. Huckel was paid pursuant to a consulting agreement which provided for the payment of fees based upon a percentage of the consideration paid by us upon completion of a licensing transaction with Dr. Huckel`s assistance. The consulting agreement expired by its terms in January 1998.

      In January 1999, we completed a private placement of 2,254,545 shares of our common stock. Dr. Hubert Huckel and Mr. Michael Hsu, directors of Titan, participated in the offering by purchasing 100,000 and 5,272 shares, respectively.

      We believe that all of the transactions set forth above were made on terms no less favorable to us than could have been obtained from unaffiliated third parties. We have adopted a policy that all future transactions, including loans, between us and our officers, directors, principal stockholders and their affiliates must be approved by a majority of the Board of Directors, including a majority of the independent and disinterested outside directors on the Board of Directors.
      Avatar
      schrieb am 01.04.00 10:54:37
      Beitrag Nr. 23 ()
      Hi schachi, TotalStock & TuNichtGut,
      da Ihr Euch bei den `BioTechs` auskennt, was haltet Ihr denn von folgenden Firmen?

      XOMA (US: XOMA)
      XENOVA (US: XNVA)
      ZONAGEN (US: ZONA)
      Chugai (Nur Jap + Dt)

      Neuimission:
      RIGEL (US: RIGL)
      Ciao
      Avatar
      schrieb am 02.04.00 20:07:31
      Beitrag Nr. 24 ()
      Hallo Schachi,

      habe mir Immunogen wieder gekauft, Titan kaufe ich auch wieder ebenso Avant und Sciclone Pharmaceuticals (Nasdaq:SCLN), die sind mir am Freitag durch die Lappen gegangen, wollte keiner mehr hergeben...

      Schaun wir mal, könnte bald wieder losgehen, vorallem wenn die Inetzahlen nicht so toll ausfallen, darin sehe ich auch die Gefahr.

      TS
      Avatar
      schrieb am 02.04.00 20:46:23
      Beitrag Nr. 25 ()
      Hallo BL,

      ja schau dir mal den Langfristchart von XOMA an, 3 Jahre 1998 waren die schonmal bei 8. Dafür haben die aber bei diesem Hype noch nicht viel zugelegt, warum?

      TS
      Avatar
      schrieb am 05.04.00 22:30:24
      Beitrag Nr. 26 ()
      NASDAQ SCHLUSSKURS 33,25 gestern im Tagestief 23,00 das halten meine Nerven nicht aus! Glaub aber das es jetzt weiter hoch geht mit Titan.
      Schöne Nacht wünscht Wagusch
      Wkn 914404 nicht vergessen
      Avatar
      schrieb am 26.04.00 23:28:46
      Beitrag Nr. 27 ()
      Warum hört man nichts mehr über TITAN ??? Ist die Aktie schon tot ??
      Würde mich über einen neuen Beitrag freuen!
      Avatar
      schrieb am 27.04.00 22:33:20
      Beitrag Nr. 28 ()
      Heute plus 10% an der Nasdaq nach einer Empfehlung mit Kursziel 46$.
      Für mich ist Titan ein Topinvesment und bleibe langfrißtig investiert!
      Avatar
      schrieb am 28.04.00 22:25:09
      Beitrag Nr. 29 ()
      Heute wieder +17%.Will hier nicht pushen aber von 6 Analysten wird Titan auf Strong Buy gestuft.Unter http://www.juchu.de könnt ihr noch einiges mehr erfahren.
      Avatar
      schrieb am 01.05.00 22:27:25
      Beitrag Nr. 30 ()
      Wieder +15% !!! Irgendetwas ist hier im Gange. Innerhalb weniger Tage +40%!Das ist nicht normal.Das Schizophrenie-Mittel steht kurz vor der
      Markteinführung, kann mir sonst keinen anderen Grund vorstellern für den steilen Anstieg.Mir sollst recht sein.
      Avatar
      schrieb am 02.05.00 22:29:25
      Beitrag Nr. 31 ()
      Heute -10% wie bei vielen Biotechwerten aber egal die Boerse ist keine Einbahnstraße morgen siehts wieder besser aus!
      Avatar
      schrieb am 03.05.00 09:27:37
      Beitrag Nr. 32 ()
      So, endlich kann man wieder seinen PC
      einschalten, ohne die tastatur voll zu heulen.
      great news und empfehlungen in USA.
      KZ: 60E Ende des Jahres und dann gehts richtig ab.
      Avatar
      schrieb am 04.06.00 23:03:30
      Beitrag Nr. 33 ()
      Gibts was neues zu TITAN ? Ist ja endlich wieder auf dem Weg nach Norden!
      Avatar
      schrieb am 29.06.00 13:42:12
      Beitrag Nr. 34 ()
      gestern gut an der Nasdaq abgeschlossen. Heute in Berlin gute 7%. Gibt es irgendwo neue Nachrichten bzw. Geruechte?
      Avatar
      schrieb am 29.06.00 22:42:45
      Beitrag Nr. 35 ()
      hallo,

      zumindest gibt es gerüchte, dass die erprobung mit CEAVAC sehr gut läuft ( dahinter steht Novartis )..... aber sind nur gerüchte die ich im yahoo board aufgeschnappt habe... hoffe es geht so weiter... auf CNBC soll ein amerikanischer analyst titan als die neue AMGEN bezeichnet haben.... was für eine schöne vorstellung!!!

      wenn ihr auf der suche nach etwas total unterbewerteten seid dann schaut euch FLAMEL an 901606 -- wird nur in berlin gehandelt (limitieren!!!) die wird sich sehr gut entwickeln... im bereich insulin (basulin) tätig hauptsächlich, naja nur so ein tip... make your own DD

      schachi
      Avatar
      schrieb am 05.07.00 09:14:56
      Beitrag Nr. 36 ()
      hi leute

      seht euch doch mal den Chart von Titan Pharmaceuticals an.
      Langsam kommen wir wieder zum 52 Wochen hoch, und wenn in naher Zukunft das Medikament
      "iloperidon" für schizophrenie rauskommt, na dann gehts richtig los.

      ciao
      Avatar
      schrieb am 06.07.00 13:27:17
      Beitrag Nr. 37 ()
      An cineman:

      Hast du irgendeinen Zeitpunkt für die Zulassung des Medikaments?
      Avatar
      schrieb am 07.07.00 11:40:40
      Beitrag Nr. 38 ()
      hi quickly

      das medikament ist in Phase III und wird voraussichtlich wenn alles klappt nächstes Jahr auf den markt kommen....
      Avatar
      schrieb am 27.07.00 08:18:33
      Beitrag Nr. 39 ()
      Guta Aussichten!!!:
      Company Press Release
      Titan Pharmaceuticals Acquires Novel Agent for the Treatment of Cancer and Viral Disease
      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--July 20, 2000--Titan Pharmaceuticals Inc. (AMEX: TTP - news) announced today that it has acquired worldwide rights to a novel, proprietary, experimental agent for the potential treatment of cancer and other conditions, including HIV infection. The product is an orally active agent that has completed initial Phase I clinical testing. Titan plans to begin Phase II clinical development in the treatment of certain cancers, and also evaluate its potential utility in other indications, including HIV infection.

      The agent, gallium maltolate, contains an oral form of gallium, a semi-metallic element that is known to concentrate in malignant tumors and sites of infection. In previous pilot clinical studies, intravenously administered gallium has demonstrated preliminary evidence of anti-tumor activity in several cancer indications, including multiple myeloma, lymphoma and bladder cancer. Recent in vitro data indicate that gallium may also have potential for the treatment of HIV infection.

      Titan believes gallium maltolate may unlock the therapeutic potential of gallium, by providing a unique orally active formulation for treatment of cancer and other diseases. Recent Phase I studies of gallium maltolate have demonstrated a good safety profile, with attainment of potentially therapeutic serum drug levels, and pharmacokinetics that support twice a day or once a day dosing.

      Dr. Christopher Chitambar, Professor of Medicine at the Medical College of Wisconsin stated, ``Previous clinical studies of intravenous gallium have shown promise in the treatment of a number of cancers and cancer-related conditions. An orally bioavailable agent such as gallium maltolate offers numerous potential advantages, and could provide an important new component to the therapy of several types of cancer.`` Dr. Chitambar has extensive research and clinical experience with the therapeutic applications of novel compounds in the treatment of cancer.

      ``We are very pleased to acquire rights to this unique proprietary therapeutic agent,`` commented Dr. Louis R. Bucalo, Chairman, CEO and President of Titan. ``Gallium maltolate may provide the best practical means for utilizing the novel anti-cancer activity of gallium, and we look forward to initiating further clinical testing.``

      With the addition of this new agent, Titan now has nine products in development, with seven in clinical testing. Titan is acquiring the product through the acquisition of GeoMed, Inc. a privately held California company founded for development of the agent. The completion of the acquisition is subject to customary closing conditions.

      Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases.

      The press release may contain ``forward-looking statements``within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company`s development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company`s drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company`s drug candidates that could slow or prevent product markets, the uncertainty of patent protection for the Company`s intellectual property or trade secrets and the Company`s ability to obtain additional financing if necessary. Such statements are based on management`s current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
      Avatar
      schrieb am 14.08.00 12:42:15
      Beitrag Nr. 40 ()
      hi leute

      wie man wieder mal merkt steckt in Titan mehr potential als in einer anderen "Drug-company".

      Zomaril wird das Produkt von Pfizer Killen, soviel ist sicher.

      Der Kurs wird langsam in Amerika wieder entdeckt, was man am Volumen erkennt. FR -->156.100

      naja, ihr werdet schon sehen wo sich diese Aktie in einem Jahr befindet.

      schöne grüße
      cineman
      Avatar
      schrieb am 13.09.00 12:41:12
      Beitrag Nr. 41 ()
      Bei CNBC wurde Titan Pharmaceuticals mittlerweile auf strong buy gesetzt. Der Trend ist nun auch begründet. Titan Pharmaceuticals geht immer gleichmässig nach oben.
      Avatar
      schrieb am 13.09.00 16:44:28
      Beitrag Nr. 42 ()
      stimmt.
      ttp war letzte woche kurz vor ath,ist dann aber durch die negative
      nasdaq leider nicht durchgebrochen.
      ttp haelt sich bei dem momentan negativen umfeld ganz gut.
      dann warten wir mal auf die positiven maerkte.
      piddy
      Avatar
      schrieb am 15.09.00 08:50:19
      Beitrag Nr. 43 ()
      About Market Edge
      Technical Terms Explained
      Need new stock ideas? Click Here

      Second Opinion® Weekly - TTP
      (Click here for how to use Second Opinion.)
      Symbol: TTP
      Name: TITAN PHARMACEUTICAL
      Exchange: AMEX Close as of week ending
      9/8/00


      Opinion
      Opinion LONG Opinion Date 08/14/00 Opinion Price 42.00
      Score 0 C-Rate 0.0

      Recommendation
      Stock is a Strong Buy.


      Comment
      Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
      Chart pattern indicates a Weak Upward Trend.
      Relative Strength is Bullish.
      Up/Down volume pattern indicates that the stock is under Accumulation.
      The 50 day Moving Average is rising which is Bullish.
      The 200 day Moving Average is rising which is Bullish.
      Look for Support at 43.72


      Week`s Activity (Close as of week ending 9/8/00)
      Week Close 48.00 Week Change 0.62
      Week Open 47.63 Week High 49.94 Week Low 43.00

      Price Analysis
      Yr. High 53.00
      Yr. Low 6.75
      MO Chg.(%) 30.2
      Resistance N/A
      Support 43.72
      SELL STOP 41.88
      Volatility(%) 5.7

      Moving Average Analysis
      Type Price % Slope
      10 Day 46.15 104 UP
      21 Day 44.04 109 UP
      50 Day 41.03 117 UP
      200 Day 31.17 154 UP

      Volume Analysis
      Ave Daily Volume (00) 1184
      MO Chg.(%) -15.8
      U/D Ratio 0.7
      U/D Direction UP

      Technical Analysis
      MACD ST BL
      MACD LT BL
      50-Day R.S. 1.09
      STO(Slow %K) 73
      STO(Fast %K) 72
      Wilder`s RSI 65
      Bollinger Bands 19
      Power Rating 82
      Avatar
      schrieb am 16.09.00 18:10:09
      Beitrag Nr. 44 ()
      hey
      ooops,8% abfahrt.
      aber,
      hold on,stay long
      gruss,piddy
      Avatar
      schrieb am 25.09.00 15:04:11
      Beitrag Nr. 45 ()
      Habe gerade gelesen, daß die Resultate für Zomaril draußen sind :positve Ergebnisse!! Das wird dem Kurs mächtig auf die Sprünge helfen.
      Avatar
      schrieb am 25.09.00 15:39:50
      Beitrag Nr. 46 ()
      Hier ist die original Nachricht:

      Monday September 25, 8:27 am Eastern Time
      Titan`s Zomaril has positive Phase III results
      SOUTH SAN FRANCISCO, Calif., Sept 25 (Reuters) - Titan Pharmaceuticals (AMEX:TTP - news), a biopharmaceutical firm, on Monday said Phase III trials for its schizophrenia treatment Zomaril yielded positive safety and efficacy data.
      Avatar
      schrieb am 26.09.00 08:38:26
      Beitrag Nr. 47 ()
      Und gestern ging es ab!!!!!!!!!! +21% Endstand: 57.20$$$$$$$

      Diese Aktie hat noch sehr viel Platz nach oben!!!

      Symbol: TTP
      Name: TITAN PHARMACEUTICAL
      Exchange: AMEX Close as of week ending
      9/22/00


      Opinion
      Opinion LONG Opinion Date 08/14/00 Opinion Price 42.00
      Score 0 C-Rate 0.0

      Recommendation
      Stock is a Strong Buy.


      Comment
      Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
      Chart pattern indicates a Weak Upward Trend.
      Relative Strength is Bullish.
      Up/Down volume pattern indicates that the stock is under Accumulation.
      The 50 day Moving Average is rising which is Bullish.
      The 200 day Moving Average is rising which is Bullish.


      Week`s Activity (Close as of week ending 9/22/00)
      Week Close 47.25 Week Change 1.75
      Week Open 45.00 Week High 47.38 Week Low 40.25

      Price Analysis
      Yr. High 53.00
      Yr. Low 6.75
      MO Chg.(%) 8.9
      Resistance N/A
      Support N/A
      SELL STOP 42.50
      Volatility(%) 6.3

      Moving Average Analysis
      Type Price % Slope
      10 Day 45.87 103 DOWN
      21 Day 45.87 103 UP
      50 Day 41.81 113 UP
      200 Day 32.81 144 UP

      Volume Analysis
      Ave Daily Volume (00) 1452
      MO Chg.(%) 64.1
      U/D Ratio 0.9
      U/D Direction UP

      Technical Analysis
      MACD ST BR
      MACD LT BL
      50-Day R.S. 1.36
      STO(Slow %K) 52
      STO(Fast %K) 98
      Wilder`s RSI 58
      Bollinger Bands 19
      Power Rating 87


      Second Opinion® Weekly is updated each week on Saturday morning.
      Avatar
      schrieb am 26.09.00 09:02:09
      Beitrag Nr. 48 ()
      Wie hoch wird den das Umsatzpotential für Zomaril geschätzt?
      2. Frage, gibt es nicht eine Internetseite, auf der man das ergründen könnte?

      x Thomas
      Avatar
      schrieb am 01.10.00 12:26:31
      Beitrag Nr. 49 ()
      Hallo Ihr Klugscheißer,
      die Aussichten für Titan sind überdimensional. Mein Rat einsteigen bevor der Zug abgefahren ist. Die Aktie erwartet eine Kurssteigerung um fast 500%.

      Lege mich jetzt zurück zum absahnen.

      Connie-Superhirn
      Avatar
      schrieb am 01.10.00 22:27:45
      Beitrag Nr. 50 ()
      also connie-superhirn

      die 500% werden wir schon machen, aber JETZT noch nicht !
      ...gebt Titan Pharm. etwas Zeit......dann wird jeder gut aussteigen.

      seriousgu<
      Avatar
      schrieb am 04.10.00 18:32:40
      Beitrag Nr. 51 ()
      hey
      nach dem enormen anstieg(wg.zomaril)haben wir in den letzten tagen
      eine enorme abfahrt bei ttp gesehen.
      53$ sollte als block stehen,muss man die kommenden tage beobachten.
      der naechste block waere wohl bei 48$.
      man sollte aufpassen,und,wenn man investieren moechte,schon mal langsam einige stuecke einsameln.denn,ttp ist eine recht aussichts-
      reiche firma.
      blockbuster"zomaril"wird auf ca.1mrd$/jahr geschaetzt.
      gruss,piddy
      Avatar
      schrieb am 05.10.00 00:16:01
      Beitrag Nr. 52 ()
      Ein erfolgreicher test des letzten ATH wird von
      charttechnikern, als bullish interpetiert.
      Also augen auf die nächsten tage und... eventuel nachkaufen
      Avatar
      schrieb am 06.10.00 16:51:39
      Beitrag Nr. 53 ()
      hey
      abfahrt beendet?
      gestern das erste mal seit mehreren tagen im gruenen geschlossen.
      53$ haben sich als guter block erwiesen.volumen hat merklich ab-
      genommen,die shorties scheinen wohl raus zu sein.
      gruss,piddy
      Avatar
      schrieb am 13.10.00 15:37:54
      Beitrag Nr. 54 ()
      hey
      db alex brown ret.strong buy at ttp
      gruss,piddy
      Avatar
      schrieb am 21.10.00 10:30:01
      Beitrag Nr. 55 ()
      HALLO TITAN FANS !!!!
      Ist ja ganz schön mau hier mit Informationen !
      Aber ich versuche es trotzdem mal . Kann mir vieleicht genauere Informationen Posten
      über dieses Unternehmen !??? Suche noch einen Wert für mein BIOTECH DEPOT !!!!!
      Avatar
      schrieb am 27.10.00 17:50:46
      Beitrag Nr. 56 ()
      hey
      what the fuck is going on?-rien-
      keine news,nichts.
      ttp bewegt sich nur seitwaerts oder runter,rauf,aber immer gleicher
      level.mit die langweiligste aktie in meinem depot.
      im vergleich zu anderen bio`s in den letzten wochen-underperformer.
      gruebel,gruebel.
      gruss,piddy
      Avatar
      schrieb am 01.11.00 16:43:20
      Beitrag Nr. 57 ()
      @ alle,
      könnte Heute ein Biotag (+2%) werden und unsere Titan ist endlich dabei (44$ +)!!!
      Hatte schon Angst, sie würde bis 33$ Unterstützung fallen.
      Wer kann mir sagen, wo ich Realtimekurse von ttp bekomme?
      Unter Island läuft mit ttp nichts, vielleicht wegen Amex Listing?
      mfg nino
      Avatar
      schrieb am 08.11.00 15:15:35
      Beitrag Nr. 58 ()
      Hallo! Gibt es keine Leute, die sich für Titan interessieren?
      Sind die letzten tage doch gut gelaufen! Meldet euch mal
      Avatar
      schrieb am 08.11.00 16:39:26
      Beitrag Nr. 59 ()
      Wollte mich nur melden und sagen daß ich ebenfalls Titan in meinem Depot habe und sie auch ne Weile halten werde, wenn nicht sogar noch nachgekaufe , mal sehen!
      Aber 500%, naja abwarten, bin ja kein Pessimist, aber noch spielt Titan nicht in der ersten Liga, das kommt aber vielleicht noch!
      Gruß Erikson
      Avatar
      schrieb am 14.11.00 18:58:20
      Beitrag Nr. 60 ()
      Hallo,

      hier findet Ihr die Zahlen vom 3. Quartal:

      http://biz.yahoo.com/bw/001114/ca_titan_p_2.html
      Avatar
      schrieb am 24.07.01 09:59:48
      Beitrag Nr. 61 ()
      Monday July 23, 9:20 am Eastern Time
      Press Release
      SOURCE: SciClone Pharmaceuticals
      SciClone`s ZADAXIN(R) Approved as Cancer Treatment in the Philippines
      SAN MATEO, Calif., July 23 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced that ZADAXIN®, the Company`s lead immune system enhancer (ISE) drug, has been approved in The Philippines as an adjuvant to chemotherapy for the treatment of various cancers. ZADAXIN previously was approved in The Philippines for the treatment of both hepatitis C and hepatitis B.

      This marks the first time ZADAXIN has been approved specifically for cancer treatment, although in some countries ZADAXIN has been approved for use as an immune system enhancer (ISE) drug without limitation to specific indications. The cancer approval was based on previously reported clinical studies conducted by investigators both in the U.S. and in Italy.

      ``Clearly, our U.S. hepatitis C phase 3 program is currently the lead corporate imperative, but it is gratifying to receive the first specific regulatory recognition of the ongoing clinical and scientific work that is focused on using ZADAXIN to treat certain cancers,`` said Donald R. Sellers, SciClone`s President and Chief Executive Officer. ``The development of ZADAXIN`s cancer therapy related clinical experience data and safety base is a growing effort.``

      Sellers also noted that ZADAXIN currently is being used in two company-sponsored phase 2 U.S. trials for liver cancer, one in combination with transarterial chemoembolization (TACE) and one using radio frequency ablation (RFA), the most widely used procedures for liver tumors that are no longer amenable to surgical resection or liver transplantation. A trial also is underway in Australia using ZADAXIN in a pure immunotherapy combination regimen for the treatment of advanced malignant melanoma.

      ZADAXIN is a synthetic preparation of thymosin alpha 1, a peptide that occurs naturally in humans and is an immune system enhancer (``ISE``) that helps stimulate, maintain and direct the body`s antiviral or anticancer responses. It has been administered to over 3,000 subjects in over 70 clinical trials covering a broad range of diseases and to many thousands of patients commercially around the world with virtually no serious drug related adverse events or toxicities. ZADAXIN is approved for sale in 24 countries principally for the treatment of hepatitis B and hepatitis C, and also in certain countries as a vaccine adjuvant for patients with weakened immune systems and as an adjuvant to chemotherapy for the treatment of various cancers. ZADAXIN currently is in a phase 3 program in the U.S. in combination with Pegasys®, pegylated interferon alfa-2a, for the treatment of hepatitis C; a phase 2 program in combination with lamivudine for the treatment of hepatitis B; and in two phase 2 trials for the treatment of liver cancer. A phase 3 ZADAXIN program for European marketing registration currently is being planned for one or more indications that complement the Company`s U.S. clinical program. ZADAXIN is also in clinical trials in Japan and Australia.

      SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world`s most serious diseases. The Company has focused its current product development and commercialization activities on hepatitis C, cancer, hepatitis B, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company`s Investor Relations Department at 800-724-2566. SciClone`s Common Stock is listed on The Nasdaq National Market® under the symbol SCLN.

      The information in this press release includes certain forward-looking statements concerning the Company`s current expectations regarding future events, including the commencement of clinical trials in Europe and the prospective development, efficacy and commercialization of ZADAXIN immunotherapy for cancer. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties that may cause actual results to differ from those stated in this release. These risks and uncertainties include uncertainties as to the timing of enrollment and potential success of the Company`s ZADAXIN clinical trials in hepatitis C, hepatocellular carcinoma and melanoma, the speed with which patients are enrolled in the trials and programs, unexpected adverse results to patients during the trials and programs, and other unexpected delays or other events that could prolong the studies or result in unanticipated expense. Additional risks and uncertainties also include those reflected in the Company`s filings with the Securities and Exchange Commission, particularly the Company`s Annual Report on Form 10-K for the year ended December 31, 2000.


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      +0,44
      -15,43
      +0,69
      +3,62
      +0,74
      -0,30
      +2,66
      +0,11
      0,00
      0,00
      Titan Pharmaceuticals--die Chance für 2000